阿斯利康:伟立瑞在华获批用于治疗成人全身型重症肌无力患者
Core Viewpoint - AstraZeneca announced the approval of Ultomiris (generic name: ravulizumab injection) in China for use in combination with standard treatment for adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) [1] Group 1 - Ultomiris has already been approved in the United States, European Union, Japan, and other regions for treating adult patients with anti-AChR antibody-positive gMG [1] - The drug has received multiple indications in various countries and regions globally [1]